Across TCGA pan-cancer cohorts, TMEM184B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TMEM184B data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher TMEM184B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM184B expression acts as an unfavorable survival marker.

SKCM and ACC are the cancer types where TMEM184B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	II,III,IV	0.149	0.712	<.001	12	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: TMEM184B tumor-vs-normal RNA expression · all TMEM184B data types